Skip to main content
. Author manuscript; available in PMC: 2006 May 9.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1482–1494. doi: 10.1016/j.ijrobp.2005.11.045

Fig. 3.

Fig. 3

Enhanced cell-killing effects of Ad/TRAIL-F/RGD plus radiotherapy in esophageal adenocarcinoma cells but not in NHLF by XTT assay. Four cell lines were treated with Ad/TRAIL-F/RGD at the indicated MOIs and radiation at the indicated doses. Cell viability was determined by the XTT assay 4 days after gene therapy and 3 day after radiotherapy. Cells treated with PBS were used as the control, with their viability set at 1. Each experiment was performed in quadruplicate and repeated at least twice. The values shown are the means of quadruplicate assay results. Bars, standard deviation. TRAIL: Ad/TRAIL-F/RGD, GFP: Ad/CMV-GFP (vector control).